Peroxisome proliferator-activated receptor γ: The more the merrier?

European Journal of Clinical Investigation

Volumn 35, Issue 2, 2005, Pages 82-92

  Argmann, C A ^a   Cock, T A ^a   Auwerx, Johan ^a,b  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

Atherosclerosis; Longevity and bone; Metabolism; Mouse models; PPAR

Indexed keywords

ADIPOKINETIC HORMONE; ADIPONECTIN; CELL NUCLEUS RECEPTOR; FATTY ACID; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RESISTIN; SIRTUIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; BONE MASS; CALORIC INTAKE; CELL DIFFERENTIATION; CONFERENCE PAPER; CONTROLLED STUDY; DROSOPHILA; ENERGY METABOLISM; FATTY LIVER; GENETIC VARIABILITY; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIVER; LONGEVITY; MACROPHAGE; METABOLIC SYNDROME X; MOUSE; MUSCLE TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ADIPOSE TISSUE; ANIMALS; ARTERIOSCLEROSIS; BONE AND BONES; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIVER; LONGEVITY; MICE; MUSCLES; OBESITY; PPAR GAMMA;

EID: 13544258629     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01456.x     Document Type: Conference Paper

References (114)

1. Mann NJ. Paleolithic nutrition: what can we learn from the past? Asia Pac J Clin Nutr 2004;13:S17-23.
2. Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologia 1999;42:1033-49.
3. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-4.
4. Burdge GC, Jones AE, Frye SM, Goodson L, Wootton SA. Effect of meal sequence on postprandial lipid, glucose and insulin responses in young men. Eur J Clin Nutr 2003;57:1536-44.
5. Friedman JM. Modern science versus the stigma of obesity. Nat Med 2004;10:563-9.
6. Sanders TA. Dietary fat and postprandial lipids. Curr Atheroscler Rep 2003;5:445-51.
7. Larsen TM, Toubro S, Astrup A. PPARγ agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy? Int J Obes Relat Metab Disord 2003;27:147-61.
8. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115 (Suppl. 8A):42S-8S.
9. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
10. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 2002;16:27-32.
11. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999;4:611-7.
12. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator activated receptor (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J Lipid Res 1996;37:907-25.
13. Norman RA, Thompson DB, Foroud T, Garvey WT, Bennett PH, Bogardus C et al. Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11Q21 Q22. Am J Hum Genet 1997;60:166-73.
14. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus. Implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2004;4:257-91.
15. Knouff C, Auwerx J. PPARγ calls for activation in moderation. Lessons from genetics and pharmacology. Endocr Rev 2004;25:899-918.
16. Deeb S, Fajas L, Nemoto M, Laakso M, Fujimoto W, Auwerx J. A Pro 12 Ala substitution in the human peroxisome proliferator-activated receptor γ2 is associated with decreased receptor activity, improved insulin sensitivity, and lowered body mass index. Nat Genet 1998;20:284-7.
17. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
18. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-γ2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun 2000;268:178-82.
19. Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ. A functional variant in the peroxisome proliferator-activated receptor γ2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003;52:1864-71.
20. Pisabarro RE, Sanguinetti C, Stoll M, Prendez D. High incidence of type 2 diabetes in peroxisome proliferator-activated receptor γ2 pro12Ala carriers exposed to a high chronic intake of trans fatty acids and saturated fatty acids. Diabetes Care 2004;27:2251-4.
21. Barbieri M, Bonafe M, Rizzo MR, Ragno E, Olivieri F, Marchegiani F et al. Gender-specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR) γ2 with longevity. Exp Gerontol 2004;39:1095-100.
22. Yliharsila H, Eriksson JG, Forsen T, Laakso M, Uusitupa M, Osmond C et al. Interactions between peroxisome proliferator-activated receptor-γ2 gene polymorphisms and size at birth on blood pressure and the use of antihypertensive medication. J Hypertens 2004;22:1283-7.
23. Pihlajamaki J, Vanhala M, Vanhala P, Laakso M. The Pro12Ala polymorphism of the PPAR γ2 gene regulates weight from birth to adulthood. Obes Res 2004;12:187-90.
24. Agarwal AK, Garg A. A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002;87:408-11.
25. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 2002;143:998-1007.
26. Hegele RA, Cao H, Frankowski C, Mathews ST, Leff T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 2002;51:3586-90.
27. Savage DB, Tan GD, Acerini CL, Jebb SA, Agostini M, Gurnell M et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ. Diabetes 2003;52:910-7.
28. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-3.
29. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New Engl J Med 1998;339:953-9.
30. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-95.
31. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K et al. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
32. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPARγ deficiency. J Clin Invest 2000;105:287-92.
33. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice. Proc Natl Acad Sci USA 2003;100:14457-62.
34. He W, Barak Y, Hevener A, Olson P, Liao D, Le J et al. Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003;100:15712-7.
35. Imai T, Takakuwa R, Marchand S, Dentz E, Bornert JM, Messaddeq N et al. Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 2004;101:4543-7.
36. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R et al. Organization, promoter analysis and expression of the human PPARγ gene. J Biol Chem 1997;272:18779-89.
37. Fajas L, Fruchart JC, Auwerx J. PPARγ 3 mRNA. A distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 1998;438:55-60.
38. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig A, Flier JS. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1997;272:20230-5.
39. Saladin R, Fajas L, Dana S, Halvorsen YD, Auwerx J, Briggs M. Differential regulation of peroxisome proliferator activated receptor γ1 (PPARγ1) and PPARγ2 mRNA expression in early stages of adipogenesis. Cell Growth Differentiation 1999;10:43-8.
40. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS. PPARgamma knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis. Genes Dev 2002;16:27-32.
41. Zhang J, Fu M, Cui T, Xiong C, Xu K, Zhong W et al. Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 2004;101:10703-8.
42. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-76.
43. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM et al. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest 2003;111:737-47.
44. Morris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC et al. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003;112:608-18.
45. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P et al. Muscle-specific PPARγ deletion causes insulin resistance. Nat Med 2003;9:1491-7.
46. Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu CH et al. Targeted elimination of peroxisome proliferator-activated receptor γ in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003,23:7222-9.
47. Chawla A, Boisvert WA, Lee C, Laffitte BA, Barak Y, Joseph SB et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001;7:161-71.
48. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S et al. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002;22:2607-19.
49. Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI et al. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev Cell 2003;5:657-63.
50. Tsai YS, Kim HJ, Takahashi N, Kim HS, Hagaman JR, Kim JK et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARγ. J Clin Invest 2004;114:240-9.
51. Hegele RA, Leff T. Unbuckling lipodystrophy from insulin resistance and hypertension. J Clin Invest 2004;114:163-5.
52. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPARγ agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004;43:661-6.
53. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidarive stress in diet-induced obesity. Hypertension 2004;43:48-56.
54. Rocchi S, Picard F, Vamecq J, Gelman L, Potier N, Zeyer D et al. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001;8:737-7.
55. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000;355:1008-10.
56. Yki-Jarvinen H, Thiazolidinediones. N Engl J Med 2004;351:1106-18.
57. Picard F, Auwerx J. PPARγ and glucose homeostasis. Annu Rev Nutr 2002;22:167-97.
58. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005 (in press).
59. Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O et al. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor γ. Endocrinology 2004;145:1527-38.
60. Burnstein KL, Luetje CW. Hormone resistance: it's SMRT to fight repression. Endocrinology 2004;145:1525-6.
61. Fukui Y, Masui S, Osada S, Umesono K, Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPARγ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 2000;49:759-67.
62. Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties. J Biol Chem 1998;273:32679-84.
63. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE et al. A selective peroxisome proliferator-activated receptor-gamma (PPARγ) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000;14:1425-33.
64. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E et al. A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002;16:2628-44.
65. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K et al. Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001;108:1001-13.
66. Rangwala SM, Lazar MA. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. Trends Pharmacol Sci 2004;25:331-6.
67. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des 2004;10:2779-86.
68. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARγ expression in osteoblasts. Biochem Biophys Res Commun 1999;260:122-6.
69. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J et al. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435-40.
70. Klein RF, Allard J, Avnur Z, Nikolcheva T, Rotstein D, Carlos AS et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15. Science 2004;303:229-32.
71. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6.
72. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-55.
73. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S et al. Enhanced bone formation in lipodystrophic PPARγ (hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004;5:1007-12.
74. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-59.
75. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-52.
76. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D et al. The role of PPAR-γ in macrophage differentiation and cholesterol uptake. Nat Med 2001;7:41-7.
77. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature 1998;391:79-82.
78. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
79. Patel L, Charlton SJ, Marshall IC, Moore GBT, Coxon P, Moores K et al. PPARγ is not a critical mediator of primary monocyte differentiation or foam cell formation. Biochem Biophys Res Commun 2002;290:707-12.
80. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans AJ. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
81. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998;93:229-40.
82. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T et al. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 2001;21:372-7.
83. Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 2001;98:2610-5.
84. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:365-71.
85. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31.
86. Szanto A, Benko S, Szatmari I, Balint BL, Furtos I, Ruhl R et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol Cell Biol 2004;24:8154-66.
87. Repa JJ, Mangelsdorf DJ. The liver X receptor gene team: potential new players in atherosclerosis. Nate Med 2002;8:1243-8.
88. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J et al. Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003;23:859-63.
89. Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A et al. Ala12Ala Genotype of the peroxisome proliferator-activated receptor γ2 protects against atherosclerosis. J Clin Endocrinol Metab 2004;89:4238-42.
90. de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation 2003;107:2548-50.
91. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6.
92. Sekiya M, Suzuki J, Watanabe K, Funada J, Otani T, Akutsu H. Beneficial effect of troglitazone, an insulin-sensitizing antidiabetic agent, on coronary circulation in patients with non-insulin-dependent diabetes mellitus. Jpn Circ J 2001;65:487-90.
93. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-35.
94. Lane MA, de Cabo R, Mattison J, Anson RM, Roth GS, Ingram DK. The Roy Walford legacy: diet restriction from molecules to mice to monkeys to man and onto mimetics. Exp Gerontol 2004;39:897-902.
95. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science 1996;273:59-63.
96. Weindruch RWRL. The retardation of aging and disease by caloric restriction, Springfiled, IL: CC Thomas; 1988.
97. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr 2003;78:361-9.
98. Sell C. Caloric restriction and insulin-like growth factors in aging and cancer. Harm Metab Res 2003;35:705-11.
99. Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 2003;299:572-4.
100. Koubova J, Guarente L. How does calorie restriction work? Genes Dev 2003;17:313-21.
101. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002;295:2450-2.
102. Tran H, Brunet A, Grenier JM, Datta SR, Fornace AJ Jr, DiStefano PS et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 2002;296:530-4.
103. Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 2000;408:255-62.
104. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004;73:417-35.
105. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305:390-2.
106. Campisi J. Fragile fugue. p53 in aging, cancer and IGF signaling. Nat Med 2004;10:231-2.
107. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004;303:2011-5.
108. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004;14:408-12.
109. Hwangbo DS, Gersham B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 2004;429:562-6.
110. Giannakou ME, Goss M, Junger MA, Hafen E, Leevers SJ, Partridge L. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science 2004;305:361.
111. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado DO et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARγ. Nature 2004;429:771-6.
112. Anderson RM, Latorre-Esteves M, Neves AR, Lavu S, Medvedik O, Taylor C et al. Yeast life-span extension by calorie restriction is independent of NAD fluctuation. Science 2003;302:2124-6.
113. Ingram DK, Anson RM, de Cabo R, Mamczarz J, Zhu M, Mattison J et al. Development of calorie restriction mimetics as a prolongevity strategy. Ann N Y Acad Sci 2004;1019:412-23.
114. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004;430:686-9.